ABI encourages top-ups debate

The insurance industry should begin discussing the possible implications of the debate over cancer drugs, according to the Association of British Insurers (ABI). The body outlined its stance following September's victory in court for Colin Ross, a cancer sufferer who took West Sussex Primary Care Trust (PCT) to court in order to force them to supply him with the drug Revlimid. Despite the medication being prescribed in other areas, West Sussex PCT refused to supply the medication. The ABI, in anticipation of the Richards Review into the consequences of additional private drugs for NHS c...